DISEASE SEVERITY AND CONTROL IN ADULTS WITH A HISTORY OF MODERATE TO SEVERE ATOPIC DERMATITIS: RESULTS FROM A LARGE PATIENT-PHYSICIAN SURVEY IN THE UNITED KINGDOM, GERMANY, AND FRANCE

被引：2
|
作者：
Villeneuve, S. [1 ]
Gadkari, A. [2 ]
Blackburn, S. [3 ]
Anderson, P. [3 ]
Moon, R. [3 ]
Piercy, J. [3 ]
Shinde, S. [4 ]
Gomez, J. [2 ]
Eckert, L. [1 ]
机构：
[1] Sanofi, Chilly Mazarin, France
[2] Regeneron, Tarrytown, NY USA
[3] Adelphi Real World, Bollington, England
[4] Sanofi, Bridgewater, NJ USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.1436
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY120
引用
收藏
页码：A596 / A596
页数：1
相关论文
共 30 条
  • [21] First results from the observational up-tained study on effectiveness and disease control in patients with moderate to severe atopic dermatitis treated with upadacitinib
    Weidinger, S.
    Schadeck, T.
    Mortazawi, D.
    Haeusler-Mehlhorn, P.
    Lupp, C.
    Mosch, T.
    Fritz, B.
    Lauffer, F.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (09) : B11 - B11
  • [22] Impact of disease location on burden of illness in patients with moderate-severe Crohn's disease: A real-world survey in the United States, France, Germany, Italy, Spain, and United Kingdom (5EU)
    Sikirica, M.
    Lynch, J.
    Kershaw, J.
    Lukanova, R.
    Baker, S.
    Milligan, G.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I230 - I230
  • [23] Dupilumab Maintains Long-Term Disease Control in Adults with Moderate-to-Severe Atopic Dermatitis as Measured by Well-Controlled Weeks: Results From the LIBERTY AD CHRONOS Clinical Trial
    Jashin J. Wu
    Lynda Spelman
    Jerry L. Tan
    Takafumi Etoh
    Haixin Zhang
    Brad Shumel
    Ana B. Rossi
    Dermatology and Therapy, 2021, 11 : 327 - 330
  • [24] Dupilumab Maintains Long-Term Disease Control in Adults with Moderate-to-Severe Atopic Dermatitis as Measured by Well-Controlled Weeks: Results From the LIBERTY AD CHRONOS Clinical Trial
    Wu, Jashin J.
    Spelman, Lynda
    Tan, Jerry L.
    Etoh, Takafumi
    Zhang, Haixin
    Shumel, Brad
    Rossi, Ana B.
    DERMATOLOGY AND THERAPY, 2021, 11 (02) : 327 - 330
  • [25] Treatment pattern by hormone receptors and HER2 status in patients with metastatic breast cancer in the United Kingdom, Germany, France, Spain, and Italy (EU-5): Results from a physician survey
    DeKoven, Mitch
    Bonthapally, Vijayveer
    Lee, Won Chan
    Pathak, Prathamesh
    Jiao, Xiaolong
    Ray, Saurabh
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] Rocatinlimab Improves Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Double-Blind Placebo-Controlled Phase 2b Study
    Gooderham, Melinda
    Guttman-Yassky, Emma
    Igawa, Ken
    Kabashima, Kenji
    Esfandiari, Ehsanollah
    Rylands, Angela J.
    Williams, Angela
    Nixon, Annabel
    Dent, Jennifer E.
    Simpson, Eric
    DERMATOLOGY AND THERAPY, 2024, 14 (12) : 3351 - 3366
  • [27] Persistent burden of disease in patients with Crohn's disease treated with biologic therapy: results from a real-world survey in the United States (US), France, Germany, Italy, Spain, and United Kingdom (5EU)
    Sikirica, M.
    Lynch, J.
    Kershaw, J.
    Lukanova, R.
    Baker, S.
    Milligan, G.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I292 - I293
  • [28] PATIENT-REPORTED DISEASE CONTROL IN MODERATE-TO-SEVERE CROHN'S DISEASE AND ULCERATIVE COLITIS: RESULTS FROM THE COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY
    Rubin, David
    Hibi, Toshifumi
    Bleakman, Alison Potts
    Gibble, Theresa
    Schreiber, Stefan
    Panaccione, Remo
    Dubinsky, Marla
    Kayhan, Cem
    Panni, Tommaso
    Favia, Angelo
    Flynn, Eoin J.
    Atkinson, Christian
    Travis, Simon
    INFLAMMATORY BOWEL DISEASES, 2025, 31 : S70 - S71
  • [29] Dupilumab improves patient-reported outcomes among adults with moderate-to-severe atopic dermatitis (AD) in clinical practice: 30-36 month results from the RELIEVE-AD study
    Strober, Bruce
    Chao, Jingdong
    Chuang, Chien-Chia
    Yang, Min
    Shumel, Brad
    Wang, Jessie
    Bego-Le-Bagousse, Gaelle
    Sierka, Debra
    Wang, Zhixiao
    Delevry, Dimittri
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB159 - AB159
  • [30] Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis
    Blauvelt, Andrew
    Kircik, Leon
    Schlesinger, Todd
    Pierce, Evangeline
    Burge, Russel
    Behling, Michael
    Atwater, Amber Reck
    Elmaraghy, Hany
    Armstrong, April
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2025, 36 (01)
123